These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 9951955)
21. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360 [TBL] [Abstract][Full Text] [Related]
22. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Arden-Cordone M; Siris ES; Lyles KW; Knieriem A; Newton RA; Schaffer V; Zelenakas K Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148 [TBL] [Abstract][Full Text] [Related]
24. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Ravn P; Neugebauer G; Christiansen C Bone; 2002 Jan; 30(1):320-4. PubMed ID: 11792604 [TBL] [Abstract][Full Text] [Related]
25. Medical management of Paget's disease of bone: indications for treatment and review of current therapies. Siris ES; Lyles KW; Singer FR; Meunier PJ J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020 [TBL] [Abstract][Full Text] [Related]
28. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208 [TBL] [Abstract][Full Text] [Related]
29. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257 [TBL] [Abstract][Full Text] [Related]
30. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Reginster JY Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506 [TBL] [Abstract][Full Text] [Related]
31. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P; Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476 [TBL] [Abstract][Full Text] [Related]
32. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Ralston SH; Thiébaud D; Herrmann Z; Steinhauer EU; Thürlimann B; Walls J; Lichinitser MR; Rizzoll R; Hagberg H; Huss HJ; Tubiana-Hulin M; Body JJ Br J Cancer; 1997; 75(2):295-300. PubMed ID: 9010041 [TBL] [Abstract][Full Text] [Related]
33. [Biphosphonate therapy in the management of skeletal metastases]. Grauer A; Ziegler R Orthopade; 1998 Apr; 27(4):231-9. PubMed ID: 9616882 [TBL] [Abstract][Full Text] [Related]
34. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Dunn CJ; Goa KL Drugs; 2001; 61(5):685-712. PubMed ID: 11368289 [TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates in the treatment of disorders of mineral metabolism. Singer FR; Minoofar PN Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099 [TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates: preclinical aspects and use in osteoporosis. Fleisch HA Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324 [TBL] [Abstract][Full Text] [Related]
37. Zoledronic acid: a review of its use in patients with advanced cancer. Perry CM; Figgitt DP Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327 [TBL] [Abstract][Full Text] [Related]
38. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Price PA; Faus SA; Williamson MK Arterioscler Thromb Vasc Biol; 2001 May; 21(5):817-24. PubMed ID: 11348880 [TBL] [Abstract][Full Text] [Related]
39. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis. Schlosser K; Scigalla P Scand J Clin Lab Invest Suppl; 1997; 227():21-8. PubMed ID: 9127465 [TBL] [Abstract][Full Text] [Related]
40. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Bauss F; Russell RG Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]